Albert Ko, MD
Infectious Disease · New Haven, CTNPI 1295107993
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $30,230 of the $42,644 with a category attached, or 70.9%. Merck accounts for 69.0% of it on its own, with 3 other manufacturers making up the rest. 2025 is the largest year on record at $13,950, more than ten times the $1,215 reported in 2020. Among infectious disease clinicians in CT with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 34 payments — averaging $1254.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$29K
- Pfizer$10K
- Regeneron$2K
- E.r. Squibb & Sons, L.L.C.$1K
Across 15 payments — averaging $127,380 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Regeneron$1.3M
- Merck$526K
- Takeda Pharmaceuticals U.S.A., Inc.$125K
What the payments were for
- Consulting fees$30,23071%
- Speaking & faculty fees$10,22524%
- Travel & lodging$1,8354%
- Food & beverage$3531%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 28 | $29,408 |
| Pfizer | 2 | $10,450 |
| Regeneron | 3 | $1,570 |
| E.r. Squibb & Sons, L.L.C. | 1 | $1,215 |
How this compares
$42,644 in reported general payments places this provider in the 90th percentile of 159 infectious disease providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other infectious disease in New Haven
- Onyema OgbuaguNew Haven$412K
- Frederick AlticeNew Haven$143K
- Michael VirataNew Haven$28K
- Brinda EmuNew Haven$18K
- Jason SicoNew Haven$10K
- Merceditas VillanuevaNew Haven$8K
- Scott RobertsNew Haven$7K
- Richard MartinelloNew Haven$5K
- Albert ShawNew Haven$4K
- Michael CappelloNew Haven$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.